Participant flow

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma · Source last updated 2025-01-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Cohort 1) 5mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid

   id

   FG000

   title

   Phase I 5mg Ruxolitinib

2. description

   Cohort A) non-responders to Phase I regimen, Cohort B) responders to Phase I regimen Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid

   id

   FG001

   title

   Phase II

3. description

   Cohort 2) 10mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid

   id

   FG002

   title

   Phase I 10 mg Ruxolitinib

4. description

   Cohort 3) 15mg ruxolitinib Carfilzomib: Irreversible proteasome inhibitor Ruxolitinib: Oral JAK inhibitor Dexamethasone: glucocorticoid

   id

   FG003

   title

   Phase I 15 mg Ruxolitinib

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         1

      type

      Participant currently on study and in follow up status.

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         5

      2. comment

         The Phase II component of this trial did not start.

         group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         4

      4. group Id

         FG003

         num Subjects

         3

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         4

      2. comment

         The Phase II component of this trial did not start.

         group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         4

      4. group Id

         FG003

         num Subjects

         2

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         1

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

The 10 participants who completed the Phase I component of the trial did not continue to the Phase II component of the trial. This is because the Phase II component of the trial did not open.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice